Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 19, 2024

https://www.globenewswire.com/news-release/2024/01/05/2804873/0/en/Tango-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

BOSTON, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective January 2, 2024, the Compensation Committee of Tango Therapeutics’ Board of Directors granted a non-qualified stock option to purchase 172,500 shares of its common stock and 26,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics’ 2023 Inducement Plan.

Read more at globenewswire.com

Related news for (TNGX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.